SEC 13F Intelligence

Marathon Capital Management / ADMA

Marathon Capital Management’s Adma Biologics Inc Position

Does Marathon Capital Management own Adma Biologics Inc (ADMA)? Yes — 627.4K shares worth $6M (+1.27% of its 13F portfolio) as of Q1 2026, up from 465.3K shares the prior filed quarter.

Position Value
$6M
Q1 2026
Shares
627.4K
% of Portfolio
+1.27%
Quarters Held
5
currently held

Position History ADMA

Reported value by quarter
Q1 ’25: $3MQ1 ’25Q2 ’25: $5MQ2 ’25Q3 ’25: $7MQ3 ’25Q4 ’25: $8MQ4 ’25Q1 ’26: $6MQ1 ’26filingsflow.com
QuarterSharesValue% of Portfolio
Q1 2026627.4K$6M+1.27%
Q4 2025465.3K$8M+1.83%
Q3 2025466.6K$7M+1.57%
Q2 2025283.7K$5M+1.32%
Q1 2025155.1K$3M+0.82%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Marathon Capital Management’s full portfolio or all institutional holders of ADMA.